Terry Murdock Net Worth
The estimated Net Worth of Terry L Murdock is at least $2.83 Million dollars as of 3 December 2018. Mr. Murdock owns over 3,523 units of G1 Therapeutics stock worth over $79,831 and over the last 2 years he sold GTHX stock worth over $0. In addition, he makes $2,748,750 as Chief Operating Officer at G1 Therapeutics.
Mr. Murdock GTHX stock SEC Form 4 insider trading
Terry has made over 5 trades of the G1 Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 3,523 units of GTHX stock worth $47,596 on 3 December 2018.
The largest trade he’s ever made was exercising 3,523 units of G1 Therapeutics stock on 3 December 2018 worth over $47,596. On average, Terry trades about 1,955 units every 14 days since 2017. As of 3 December 2018 he still owns at least 3,523 units of G1 Therapeutics stock.
You can see the complete history of Mr. Murdock stock trades at the bottom of the page.
Terry Murdock biography
Terry L. Murdock is the Chief Operating Officer of G1 Therapeutics Inc. Mr. Murdock has served as our Chief Operating Officer since January 2019 and served as our Senior Vice President of Development Operations from August 2017 to December 2018. Prior to joining us, Mr. Murdock served as Vice President, Development Solutions of the Oncology Center for Excellence at IQVIA Holdings Inc. (formerly Quintiles IMS Holdings, Inc.), or IQVIA, from September 2014 to August 2015, and then as Vice President, Global Head of the Oncology Center for Excellence at IQVIA from August 2015 to July 2017. Prior to his tenure with IQVIA, Mr. Murdock served as President North America and a member of the board of directors of Ergomed Clinical Research, Inc., a wholly owned subsidiary of Ergomed plc, a publicly traded British pharmaceutical services company from 2012 to August 2014. Mr. Murdock also was Senior Vice President of ILEX Oncology Inc., or ILEX, and later Genzyme Corporation, a biotechnology company, following its acquisition of ILEX from 2001 to May 2012 and Vice President of Research at The US Oncology Network, a healthcare services company from 1995 to 2001. Mr. Murdock earned his M.S. and B.S. from the University of Texas at Arlington.
What is the salary of Terry Murdock?
As the Chief Operating Officer of G1 Therapeutics, the total compensation of Terry Murdock at G1 Therapeutics is $2,748,750. There are 2 executives at G1 Therapeutics getting paid more, with John Demaree having the highest compensation of $7,466,410.
How old is Terry Murdock?
Terry Murdock is 59, he’s been the Chief Operating Officer of G1 Therapeutics since 2019. There are 6 older and 7 younger executives at G1 Therapeutics. The oldest executive at G1 Therapeutics, Inc. is Fredric Eshelman, 70, who is the Independent Director.
What’s Terry Murdock’s mailing address?
Terry’s mailing address filed with the SEC is 79 T.W. ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK, NC, 27709.
Insider trading at G1 Therapeutics
Over the last 2 years, insiders at G1 Therapeutics have traded over $51,509,269 worth of G1 Therapeutics stock and bought 1,482,753 units worth $23,467,604 . The most active insider traders include Capital Management, Llcra C…, Fredric N Eshelman, and Glenn P Muir. On average, G1 Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $994,813. The most recent stock trade was executed by Jennifer K. Moses on 18 July 2019, trading 2,000 units of GTHX stock currently worth $7,440.
What does G1 Therapeutics do?
G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
What does G1 Therapeutics’s logo look like?
Complete history of Mr. Murdock stock trades at G1 Therapeutics
G1 Therapeutics executives and stock owners
G1 Therapeutics executives and other stock owners filed with the SEC include:
- John Demaree, Chief Commercial Officer
- James Hanson, General Counsel
- Terry Murdock, Chief Operating Officer
- Mark Velleca, President, Chief Executive Officer, Director
- Garry Nicholson, Independent Chairman of the Board
- Barclay Phillips, Chief Financial Officer and Senior Vice President – Corporate Development
- Rajesh Malik, Chief Medical Officer, Senior Vice President – Research and Development
- Cynthia Schwalm, Independent Director
- Willie Deese, Independent Director
- Seth Rudnick, Independent Director
- Glenn Muir, Independent Director
- Fredric Eshelman, Independent Director
- Andrew Witty, Independent Director
- Jeff Macdonald, Head of Investor Relations/Public Relations
- Jennifer Moses, Vice President – Finance and Accounting
- Jay Strum, Chief Scientific Officer
- Clay Hatteras Venture Advis…,
- Capital Management, Llcra C…,
- Christy L Shaffer, Director
- Ventures, Inc. Med Immune, 10% owner
- Ventures, Llc Eshelman, 10% owner
- Clay Hatteras Venture Advis…,
- Mark Avagliano, Chief Business Officer